OS: Key secondary endpoint
met
Adenocarcinoma
+ time since start of first-line therapy
<9 months*
Nintedanib +
docetaxel
Placebo +
docetaxel
Median, mo
10.9
7.9
HR (95% CI)
0.75
(0.60 to 0.92)
p value
0.0073
206
167
119
92
73
51
35
16
9
3
199
154
91
62
42
25
17
12
5
1
100
80
60
40
20
0
0 4 8 12 16 20 24 28 32 36
Probability of survival (%)
Time (months)
46,8%
34,3%
20,7%
10,4%
Number at risk
Nintedanib
Placebo
Reck M,
et al
.
Lancet Oncol
. 2014;15:143-55.
* 62% of patients
